Catalyst Pharmaceuticals (NASDAQ:CPRX) PT Raised to $22.00 at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) had its price target upped by investment analysts at Truist Financial from $18.00 to $22.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective points to a potential upside of 5.77% from the stock’s previous close.

A number of other equities analysts have also issued reports on CPRX. HC Wainwright upped their target price on Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, December 21st. Piper Sandler boosted their price target on Catalyst Pharmaceuticals from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. Finally, StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $20.38.

Catalyst Pharmaceuticals Stock Up 2.6 %

Shares of CPRX opened at $20.80 on Thursday. The business’s 50 day moving average is $17.94 and its two-hundred day moving average is $14.36. Catalyst Pharmaceuticals has a 52-week low of $5.24 and a 52-week high of $22.11. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of 34.10 and a beta of 1.19.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Catalyst Pharmaceuticals had a return on equity of 28.53% and a net margin of 34.90%. The company had revenue of $57.24 million for the quarter, compared to analyst estimates of $53.80 million. On average, equities analysts expect that Catalyst Pharmaceuticals will post 0.73 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Alicia Grande sold 60,000 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $15.77, for a total transaction of $946,200.00. Following the completion of the transaction, the chief financial officer now directly owns 147,442 shares in the company, valued at approximately $2,325,160.34. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, CFO Alicia Grande sold 60,000 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $15.77, for a total transaction of $946,200.00. Following the completion of the transaction, the chief financial officer now directly owns 147,442 shares in the company, valued at approximately $2,325,160.34. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Patrick J. Mcenany sold 350,000 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $15.62, for a total value of $5,467,000.00. Following the transaction, the chief executive officer now owns 3,902,606 shares of the company’s stock, valued at $60,958,705.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 942,703 shares of company stock worth $14,867,756. 14.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $31,000. FMR LLC grew its stake in shares of Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares in the last quarter. Covestor Ltd grew its stake in shares of Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,316 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Catalyst Pharmaceuticals in the first quarter worth $62,000. Finally, KBC Group NV bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $106,000. 86.66% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

The Fly logo

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.